MOLN Molecular Partners AG
Molecular Partners AG (MOLN) is expected to report earnings on November 24, 2026, before the market open. The consensus earnings estimate is a loss of $0.46 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.0% since its last earnings release on August 25, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot.
Sector
Healthcare
Industry
Biotechnology